The law firm said it is investigating possible securities fraud after Larimar disclosed anaphylaxis cases in an ongoing Friedreich's Ataxia nomlabofusp study and shares fell sharply on Sept. 29, 2025 and June 29, 2026.
Pomerantz LLP said it is investigating claims on behalf of investors in Larimar Therapeutics, Inc. over whether the company and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. The inquiry centers on disclosures from an ongoing long-term open-label study of daily subcutaneous nomlabofusp injections in participants with Friedreich's Ataxia. On Sept. 29, 2025, Larimar reported study data it described as positive while disclosing anaphylaxis in seven participants, and the stock fell $1.72, or 33.66%, to close at $3.38. On June 29, 2026, Larimar released new study data, confirmed submission of the first section of its rolling Biologics License Application seeking accelerated approval for nomlabofusp, and disclosed an ongoing safety signal with anaphylaxis reported in 10 of 43 patients; the shares fell $0.46, or 12.57%, to close at $3.20.